The Centers for Medicare and Medicaid Services excused four drugs from being selected for Medicare price negotiation in the first round because they qualified for the small biotech exception, according to the agency.
“For initial price applicability year 2026, drug companies submitted requests and information to CMS for four drugs that were determined...